De-Risking Cardiac AI: A Clinical Due Diligence Playbook for Executives

The healthcare field’s flooded with AI pitches, all promising massive efficiencies and clinical wins. If you’re a healthcare VC, an institutional investor, or a hospital procurement officer, your job is to sift through this noise to find cardiac AI software that’s actually impactful and clinically defensible. The risk of sinking money into an unproven tool, one fueled by marketing spin instead of hard evidence, is huge.

The Imperative of Clinical Rigor in Cardiac AI

With so much Software as a Medical Device (SaMD) hitting cardiology, you need a systematic way to do due diligence. Unlike some general AI platforms, disease-specific AI, especially in cardiac care, absolutely requires deep clinical validation for patient safety, clinical efficacy, and your eventual return on investment. The real difference between some new AI toy and a clinically defensible tool is its regulatory history, the depth of its peer-reviewed studies, and whether it aligns with professional society guidelines. Your first step should always be understanding the regulatory field. For cardiac AI, the FDA’s role is to de-risk these investments. Most companies use one of two main pathways: 510(k) clearance or a De Novo classification. A 510(k) is often the faster route, as it just shows the device is substantially equivalent to something already on the market. But for genuinely new cardiac AI functions, like detecting a condition no existing device can, companies have to go through the more demanding De Novo pathway, which signals a higher bar of clinical novelty and safety even though it can take 9-12 months. Viz.ai, for example, used these pathways to get FDA-cleared triage algorithms for stroke and cardiovascular care to market, securing De Novo clearances for novel functions like Viz LVO and Viz HCM. Cleerly also navigated the FDA with its non-invasive coronary analysis tools, getting 510(k) clearances for products like Cleerly ISCHEMIA and Cleerly LABS v2.0. FDA medical device databases for 510(k) and De Novo clearances

Evaluating Regulatory Pathways and Evidence: 510(k) vs. De Novo

The specific FDA pathway a company chose tells you a lot about its cardiac AI’s novelty and the regulatory burden it’s already cleared. A 510(k) clearance, while important, might just mean the AI does a similar job to an existing device, maybe with better accuracy. A De Novo classification, on the other hand, suggests the device is tackling an unmet need or using a fundamentally new method for diagnosis or treatment. Investors and buyers should be scrutinizing the specific FDA clearance types for any major cardiac triage tool they’re looking at. But what about after the initial clearance? It’s important to know how an AI model is designed to get better over time. This is where the FDA’s Predetermined Change Control Plan (PCCP) framework comes in. Without a PCCP, every time a model is retrained on new data, it could technically trigger a whole new premarket submission, creating an unscalable regulatory nightmare that stops continuous improvement in its tracks. Companies that haven’t built their development around Good Machine Learning Practice (GMLP) principles, as defined by the FDA, Health Canada, and MHRA, are likely carrying a lot of “regulatory debt.”

The Weight of Peer-Reviewed Publications and Clinical Trials

Clinical defensibility is tied directly to solid, peer-reviewed evidence. Lots of companies will show you their internal validation data, but the gold standard will always be independent research published in a reputable medical journal. This is where you see if a disease-specific AI health platform is for real. Take Cleerly’s non-invasive coronary artery analysis tech. It’s backed up by a long list of peer-reviewed publications showing it can accurately find and measure coronary plaque, a key piece of cardiac risk assessment. In the same way, Viz.ai’s algorithms have been heavily validated, with over 125 peer-reviewed publications in top journals confirming their effectiveness in improving patient outcomes during stroke and cardiovascular emergencies. Peer-reviewed publications for Cleerly and Viz.ai When you’re looking at the evidence, you have to ask the right questions:

• Study Design: Are we talking about randomized controlled trials (RCTs), real-world evidence (RWE) studies, or just retrospective analyses? RCTs are best, but large-scale RWE studies using data from EHRs or registries can show how a tool performs in the real world.
• Sample Size and Diversity: Does the evidence come from a patient population that’s diverse enough to minimize bias and make the results generalizable?
• Clinical Endpoints: Are the endpoints actually meaningful to doctors and patients? A small bump in diagnostic accuracy is one thing, but proof of better patient outcomes (like fewer MACE events or faster time to treatment) is what really matters.
• Independent Validation: Was the research done by independent third parties, or was it all done in-house by the company’s own team?

You also have to check if the tool fits into established clinical practice. Does it align with what the American College of Cardiology (ACC) and American Heart Association (AHA) recommend in their latest guidelines for cardiac imaging and digital health? Investing in a cardiac AI that goes against what these major professional societies say is just throwing money away.

A Rigorous 3-Part Due Diligence Checklist for Medical Software Defensibility

For VCs, institutional investors, and hospital procurement officers, this simple framework can help you tell a viable clinical solution from a tech novelty.

1. Regulatory Pathway and Post-Market Surveillance

“If your AI detects a condition no existing device detects, you can’t 510(k) it, you need De Novo, which takes 9 to 12 months.”

• FDA Clearance Type: Don’t just ask if it’s cleared. Ask how. Is it a 510(k) clearance (and what’s the predicate device) or a De Novo classification? The answer tells you a lot about its novelty and the regulatory hoops it’s jumped through.
• PCCP Status: For any AI/ML model that’s supposed to learn and adapt, ask about its Predetermined Change Control Plan. A “yes” means the FDA has already approved its process for iterative improvement, which is a very good sign.
• Post-Market Performance: How do they track algorithmic drift in the real world? A good answer involves strong Quality Management Systems (QMS) and ISO 13485 certification, which are critical for monitoring performance after launch.
• Security and Privacy: This is non-negotiable. No HIPAA, HITRUST, and SOC 2 Type II certifications? That’s an immediate red flag about their data governance and a likely deal-breaker.

2. Clinical Evidence and Professional Society Alignment

“Anumana is the first ECG-AI with CPT codes, that’s a reimbursement moat investors should weight heavily.”

• Peer-Reviewed Publications: Scrutinize the number and, more importantly, the quality of their peer-reviewed papers. How many are from strong methodologies like RCTs or large-scale RWE? Go and actually verify the publication counts claimed by companies like Cleerly and Viz.ai.
• Clinical Guideline Adherence: Check the AI tool against the most recent clinical guidelines from groups like the American College of Cardiology and the American Heart Association. Does it help clinicians adhere to best practices or contradict them? American College of Cardiology clinical guidelines
• Reimbursement Pathways: Is there a clear path to getting paid for using this? Look for existing CPT codes (is it a permanent Category I code or a temporary Category III?) and any potential to get NTAP (New Technology Add-On Payment) status. A clear reimbursement strategy is what separates good tech from a good business.

3. Data Moat and AI-Native Architecture

“iRhythm’s data moat, millions of labeled ECG recordings, makes it nearly impossible for a new entrant to match their accuracy.”

• Proprietary Data Moat: What’s their unique source of data? A company’s real competitive advantage is often a proprietary, high-quality dataset that competitors can’t easily replicate. This “data moat” is what fuels better models and makes the business defensible.
• AI-Native Design: Was the company built around AI from the ground up, or is AI just a feature they bolted on to an existing product? AI-native companies have a much deeper integration and understanding of the technology’s capabilities and limits.
• Transparency and Interpretability: The regulators may not demand this yet, but can the AI explain its results? A “black box” is a hard sell to clinicians, and tools that provide some level of interpretability tend to build trust and get adopted faster.

By using this framework, you can cut through the marketing fluff and focus on what’s real. You can distinguish between the dozens of emerging cardiac AI solutions to find the ones that have true clinical defensibility, provide a real patient benefit, and offer long-term value. The future of cardiac care will certainly be AI-powered, but only the solutions built on a foundation of rigorous evidence and a sound regulatory strategy are going to be the ones that actually reshape medicine.